Login / Register

Oxford Peptide Labs-Logo
SHIPPED STRAIGHT FROM OUR FREEZER
24 MONTH SHELF LIFE
HPLC TESTED 99%+ PURITY
SHIPPED WITHIN 24 HOURS
Cagrilintide-10mg
VIAL0001
Box-01
Test HPLC
OVER 80K+
Cagrilintide-10mg
VIAL0001
Box-01
Test HPLC
OVER 80K+

Cagrilintide

£43.90

In stock
High-purity Cagrilintide lyophilized powder for research into amylin receptor agonism, satiety regulation, and metabolic weight management.

Description

Cagrilintide is a novel, long-acting acylated amylin analogue designed for research into metabolic regulation and weight management. It functions as a non-selective agonist for both amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR), mimicking the physiological effects of the endogenous hormone amylin. By targeting these pathways, Cagrilintide is investigated for its potential to induce satiety, delay gastric emptying, and regulate glucose homeostasis, particularly in the context of obesity and type 2 diabetes.

Reviews

There are no reviews yet.

Be the first to review “Cagrilintide”

Your email address will not be published. Required fields are marked *

No more offers for this product!

General Inquiries

There are no inquiries yet.

Category Tags , , Brand:
  • Download COA here:
Download COA (PDF)

Please note if you have a different Batch ID please contact us for the latest COA.

Chemical Specifications:

  • Chemical Name: Cagrilintide (Acetate)

  • Synonyms: AM-833, NN9838

  • CAS Number: 1415456-99-3

  • Molecular Formula: C194H312N54O59S2

  • Molecular Weight: 4409.01 g/mol

  • Sequence: {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2

  • Structure: Acylated peptide with disulfide bridge (Cys3–Cys8)

Description & Mechanism
Cagrilintide is a novel, long-acting acylated amylin analogue designed for research into metabolic regulation and weight management. It functions as a non-selective agonist for both amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR), mimicking the physiological effects of the endogenous hormone amylin. By targeting these pathways, Cagrilintide is investigated for its potential to induce satiety, delay gastric emptying, and regulate glucose homeostasis, particularly in the context of obesity and type 2 diabetes.

  • Metabolic Research: Investigated for its role in regulating energy balance and reducing body weight via central nervous system pathways.

  • Satiety Signalling: Acts on brainstem receptors to promote feelings of fullness and reduce food intake.

  • Glucose Homeostasis: Studies suggest potential for delaying gastric emptying and suppressing postprandial glucagon secretion.

  • Combination Studies: Frequently researched in conjunction with GLP-1 receptor agonists (e.g., Semaglutide) to evaluate synergistic effects on weight loss.

  • Formulation: Lyophilized powder.

  • Storage: -20°C for powder, -80°C for reconstituted solution.

  • Reconstitution: Bacteriostatic water or sterile saline.

  • Purity: ≥99% (HPLC)

  • Grade: Research Grade

  • Appearance: White lyophilized powder

  • Solubility: Soluble in DMSO; sparingly soluble in aqueous buffers.

For Research Use Only. Not for human consumption. Cagrilintide is an investigational peptide. Handling should be performed by qualified personnel using appropriate personal protective equipment (PPE). Avoid inhalation or contact with skin and eyes. In clinical research settings, it has been associated with gastrointestinal effects; however, this product is strictly for in vitro or animal laboratory research.

  1. Kruse, T., et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry, 64(15), 11183–11194.

  2. Enebo, L. B., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736–1748.

  3. De Block, C., et al. (2023). REDEFINE 1: Cagrilintide/semaglutide (CagriSema) s.c. once weekly vs semaglutide 2.4 mg and cagrilintide 2.4 mg in people with overweight or obesity. Diabetes, 72(Supplement_1).

In stock

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.